HDAC inhibition as an anticancer therapeutic strategy has been gaining traction over the last two decades, and has seen major success in the FDA approval of pan-HDAC inhibitor Vorinostat for treatment of cutaneous T cell lymphoma (CTCL) [12]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.